Impact of the Immune System on Response to COVID-19 Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
The study, sponsored by the University of Liege, aims to evaluate the immune response to the BNT162b2 (Comirnaty®) COVID-19 vaccine in allogeneic stem cell transplant recipients. Given the unique patient population and the urgent need for effective vaccination strategies in immunocompromised individuals, the results could inform clinical guidelines and enhance vaccine uptake in this demographic. The collaboration with Pfizer suggests potential for further partnership opportunities, particularly in expanding the understanding of vaccine efficacy in vulnerable populations. The findings may also influence market positioning for COVID-19 vaccines and related therapies, especially as booster strategies evolve.
Indication: Coronavirus Disease 2019 (Covid19)
Modality: RNA therapy
Target: SARS-CoV-2 receptor binding domain (RBD) specific IgG antibodies and T cell/B cell responses
Sponsor: University of Liege
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 14, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: SARS-CoV-2 receptor binding domain (RBD) specific IgG antibodies and T cell/B cell responses
View original source fields
Condition raw: Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms
Condition normalized: Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: SARS-CoV-2 receptor binding domain (RBD) specific IgG antibodies and T cell/B cell responses
Target normalized: SARS-CoV-2 receptor binding domain (RBD) specific IgG antibodies and T cell/B cell responses